Gentamicin and G418, two aminoglycoside antibiotics, were effective at correcting genetic mutations associated with a specific form of frontotemporal dementia. The findings are promising for the treatment of frontotemporal dementia.
Researchers report neurodegeneration associated with frontotemporal dementia could span from a reduced trophic support for neurons.
Researchers link obsessive behaviors in frontotemporal dementia to immune pathways and suggest targeting the immune system could be a new strategy for the treatment of FTD.
Researchers have identified a common mechanism in both frontotemporal dementia and neuronal ceroid lipofuscinosis.
According to researchers, FTD may be triggered by a defect in microglia.
Low levels of progranulin shown to increase the formation of amyloid beta plaques and worsen memory deficits in mouse models of Alzheimer's disease.
Researchers report retinal degeneration could be one of the earliest signs of FTD in people who have a genetic risk for the disorder.